A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm. Patients diagnosed with GISTs can face a higher risk of additional malignancies, including genitourinary cancers. Ripretinib has previously been identified as an effective inhibitor of secondary KIT mutations while in the AL. Patients with moderate- or high-risk GIST receive adjuvant imatinib therapy following surgical resection. While imatinib is considered standard-of-care, there is a lack of clinical data for the treatment among elderly patients. Surgical treatment combined with targeted therapy may improve OS and CSS in patients with GIST-SLM. A final overall survival and updated safety analysis from the phase 3 INTRIGUE study. Topline results from the pivotal phase III INVICTUS trial showed that the novel drug ripretinib improved ...